Related Experiment Video
Updated: Dec 21, 2025
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
13.3K
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness
Maria Rosaria Raspollini1, Ilaria Montagnani1, Paolo Cirri2
1Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Toscana, Italy.
The International Journal of Biological Markers
|May 12, 2020
Summary
PreImplantation Factor (PIF) is detected in moderate-to-high risk prostate cancer, showing potential as a biomarker for aggressiveness. PIF assessment may aid in evaluating prognosis in prostate cancer patients.
Area of Science:
- Oncology
- Biomarker Discovery
- Immunohistochemistry
Background:
- PreImplantation Factor (PIF) is an embryonic peptide with protective, regenerative, and immune-modulating properties.
- Synthetic PIF (sPIF) demonstrates immune-protection, regeneration, and reduction of oxidative stress.
- PIF is found in endometriotic lesions and advanced uterine cancer, suggesting a role in neoplastic processes.
Purpose of the Study:
- To investigate the presence and significance of PIF in prostate cancer specimens.
- To correlate PIF expression with Gleason score and cancer aggressiveness.
Main Methods:
- Immunohistochemistry (IHC) was used to detect PIF in 50 human prostate cancer samples.
- PIF staining was correlated with Gleason score (GS) and WHO Grade Group (GG).
Main Results:
- PIF was detected in moderate-to-high risk prostate cancers (GS 4+3 and higher).
- Positive PIF staining was observed in 50-62.5% of higher-grade prostate cancers (GG5, GG4, GG3).
- PIF was absent in normal prostate glands and low-grade cancers (GG1, GG2).
Conclusions:
- PIF detection via IHC is a potential biomarker for prostate cancer aggressiveness.
- PIF assessment may serve as a simple tool for evaluating prognosis in prostate cancer patients.
